Physician profile

Rachana Murthy

Endocrinology, Diabetes & Metabolism · Lancaster, PA

NPI 1295261923

$209.00

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$158.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Embecta Corp. $39.69 2023 Bd Nano 2nd Gen Pen Needle
Dexcom, INC. $38.92 2021-2023 Dexcom G6 Transmitter
Ascensia Diabetes Care US INC. $28.48 2023
Ascendis Pharma Endocrinology INC $22.90 2023
Alexion Pharmaceuticals, INC. $20.99 2023 Strensiq
Mallinckrodt Hospital Products INC. $16.53 2021
Lilly USA, LLC $15.38 2022
Bayer Healthcare Pharmaceuticals INC. $13.21 2023
Amgen INC. $12.90 2023 Evenity, Prolia

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rachana Murthy

$209.00

in general payments reported 2019-2025

Years
2021-2023
Top company
Embecta Corp.

https://glasscript.com/doctor/11284181/rachana-murthy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.